ClinVar

Description

The c.1867+2T>C intronic variant results from a T to C substitution two nucleotides after coding exon 15 in the MRE11A gene. This alteration was detected in 1/715 male breast cancer patients who underwent multi-gene panel testing at a clinical diagnostic laboratory (Pritzlaff M et al. Breast Cancer Res. Treat. 2017 02;161:575-586). This alteration was also identified in a cohort of 192 Spanish hereditary breast and ovarian cancer families who did not have a pathogenic variant in BRCA1 or BRCA2 (Bonache S et al. J Cancer Res Clin Oncol, 2018 Dec;144:2495-2513) as well as in a cohort of 7768 adult ovarian cancer cases of European ancestry referred to a single clinical testing laboratory (Lilyquist J et al. Gynecol Oncol, 2017 Nov;147:375-380). This variant was also identified by whole genome sequencing in an individual with an immunodeficiency disorder; it was seen in conjunction with another MRE11A deep intronic alteration (van Schouwenburg PA et al. Clin. Immunol., 2015 Oct;160:301-14). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. The resulting transcript is predicted to be in-frame and is not expected to trigger nonsense-mediated mRNA decay; however, direct evidence is unavailable. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. Based on the majority of available evidence to date, this variant is likely to be pathogenic.